Date: 3rd February 2020
The Keyrus Group, with headquarters in France, has announced the launch of Keyrus Life Science, the first Connected-CRO (C2RO - Contract Research Organisation) designed to facilitate and accelerate the digital transformation of enterprises in the health sector in the data-digital era.
Keyrus is a specialist in performance management consulting and the integration of innovative technological solutions in the Data and Digital fields. The development of Keyrus Life Science will help connect industry expertise, life data sciences and digital enablement to fully leverage both clinical research ecosystems and real-world evidence in healthcare. It will enhance the reliability, innovative capacity, agility, and, above all, speed of execution of clinical research activities.
The move will see Keyrus Life Science enable their customer to achieve digitalisation across all life science industry segments – starting from R&D cycles, to clinical stages, through to real world evidence and insights in a post-marketing setting.
https://www.prnewswire.co.uk/news-releases/keyrus-launches-keyrus-life-science-the-first-connected-cro-c2ro-designed-to-accelerate-the-health-industry-s-digital-transformation-862771051.html
Bio-IT World 2020, is a leading conference and expo uniting life science, data, informatics and IT leaders. It has announced an expanded focus on the Data Science innovations that are moving precision medicine into new frontiers, for its 19th annual event, taking place April 21-23, 2020 in Boston.
https://www.businesswire.com/news/home/20200128005512/en/Precision-Medicine-Leaps-Data-Science-Bio-IT-World
Microsoft have announced the launch of AI for Health, a new $40 million, five-year program to empower researchers and organizations with AI to improve the health of people and communities around the world.
The AI for Health initiative will focus on three key areas:
https://blogs.microsoft.com/on-the-issues/2020/01/29/ai-for-health-child-mortality/
A phase I clinical study of a new drug, DSP-1181, that was created using Artificial Intelligence (AI), has been initiated in Japan for the treatment of obsessive-compulsive disorder as an initial indication. It is claimed to be the world’s first AI-driven precision engineered drug to reach clinical trials
The joint development venture by Sumitomo Dainippon Pharma Co., Ltd. Based, in Osaka, Japan, and Exscientia Ltd., based in Oxford, UK took less than 12 months to complete the exploratory phase, over 4 times faster than the typical average time using conventional techniques.
Sumitomo Dainippon Pharma provided its experience and knowledge in drug discovery (monoamine GPCR) and Exscientia applied its Centaur Chemist™ Artificial Intelligence (AI) platform for drug discovery.
https://www.exscientia.ai/news-insights/sumitomo-dainippon-pharma-and-exscientia-joint-development
